JAK1 JH2 Domain (human, recombinant, aa 561-852)

JAK1 is a non-receptor tyrosine kinase that has roles in immune signaling. It is composed of N-terminal FERM and SH2 domains, a regulatory pseudokinase domain (JH2), and a C-terminal kinase domain. It is widely expressed and associates with class I and class II cytokine receptors at the plasma membrane. Activation of these cytokine receptors activates JAK1 and induces its dimerization and kinase activity, leading to JAK1 phosphorylation of STAT transcription factors and transcription of immune-related target genes. JAK1 signaling is inhibited by the suppressor of cytokine signaling (SOCS) proteins SOCS1, SOCS3, and SOCS5. Knockout of Jak1 in mice results in perinatal mortality and deficits in lymphopoiesis. JAK1 fusion proteins and activating mutations in JAK1 are associated with acute myeloid leukemia (AML) and T cell precursor acute lymphoblastic leukemia (ALL). JAK1 containing a valine-to-phenylalanine substitution (JAK1V617F) in the JH2 domain is associated with disease incidence in patients with polycythemia vera, a thrombotic erythrocyte hyperproliferative disorder. Cayman's JAK1 JH2 domain (human, recombinant, aa 561-852) protein can be used for binding assays and has a calculated molecular weight of 35 kDa.Synonyms: Janus-Associated Kinase 1, JTK3, Tyrosine-Protein Kinase JAK1. Purity: >90% estimated by SDS-PAGE. Source: Active recombinant human N-terminal His-tagged JAK1 JH2 domain expressed in insect cells (sf9). Amino Acids: 561-852. MW: 35 kDa. Formulation: (Request formulation change), 40 mM Tris-HCl, pH 8.0, with 110 mM sodium chloride, 2.2 mM potassium chloride, 0.04% polysorbate 20, and 20% glycerol. UniProt Accession No: P23458.